The fight against HIV is poised for a historic breakthrough as Kenya prepares to roll out Lenacapavir, the world’s first twice-yearly injectable pre-exposure prophylaxis (PrEP), by January 2026. This groundbreaking innovation, recently approved by the U.S. FDA and endorsed by the World Health Organization (WHO), promises to revolutionize HIV prevention with its unparalleled efficacy and convenience.

A New Era in HIV Prevention

Lenacapavir, developed by Gilead Sciences, represents a seismic shift in HIV prevention strategies. Unlike daily oral PrEP, which requires consistent adherence, this subcutaneous injection administered just twice a year has demonstrated near-perfect efficacy in clinical trials.

In the PURPOSE 1 trial involving cisgender women in sub-Saharan Africa, zero HIV infections were recorded among participants receiving lenacapavir, while the PURPOSE 2 trial showed a 99.9% efficacy rate among men and gender-diverse individuals. These results underscore its potential to dramatically reduce new infections, particularly among high-risk populations such as adolescent girls, young women, and key populations like sex workers and men who have sex with men.

Read also: Career Planning – What they Don’t Teach You in Medical School!

Kenya’s Pioneering Role

Kenya’s inclusion among the nine early-adopter countries for Lenacapavir rollout reflects its high HIV burden and robust healthcare infrastructure. The National AIDS and STI Control Program (NASCOP) has confirmed that the drug will be integrated into national HIV prevention programs by early 2026, complementing existing tools like oral PrEP and injectable cabotegravir. This rollout is part of a landmark agreement between the Global Fund and Gilead, ensuring low- and middle-income countries receive the drug simultaneously with wealthier nations—a first in global health equity.

Challenges and Opportunities

Despite its promise, the path to widespread Lenacapavir adoption is fraught with challenges. The drug’s U.S. list price of $28,218 per year is prohibitive for Kenya, though the Global Fund’s cost-price agreement and anticipated generic versions (projected at $25–$40 annually) could mitigate this barrier. Logistical hurdles, such as cold-chain storage and training healthcare workers, must also be addressed, particularly in rural areas with limited infrastructure.

Moreover, Kenya’s rollout coincides with a precarious funding landscape. Recent cuts to PEPFAR threaten to undermine progress, necessitating increased domestic investment and innovative financing models. Community engagement will be critical to combat stigma and misinformation, ensuring those most at risk—such as young women in high-incidence regions—can access this lifesaving tool.

The Road Ahead

Lenacapavir is not a silver bullet, but it is a transformative addition to the HIV prevention arsenal. Its success hinges on equitable access, sustained funding, and robust health systems. As Kenya prepares for this milestone, collaboration between government, NGOs, and communities will be essential to turn scientific promise into real-world impact.

For medical professionals, this moment calls for proactive education and advocacy. By staying informed and engaging with national guidelines, healthcare providers can help usher in a new chapter in Kenya’s fight against HIV—one where twice-yearly injections could finally bend the curve of the epidemic.

*Sources: WHO, Global Fund, NASCOP, and clinical trial data.